• Pablo Sanchez-Salcedo, Juan Berto, Juan P de-Torres, Arantzazu Campo, Ana B Alcaide, Gorka Bastarrika, Jesús C Pueyo, Alberto Villanueva, José I Echeveste, Maria D Lozano, María J García-Velloso, Luis M Seijo, Javier García, Wenceslao Torre, Maria J Pajares, Ruben Pío, Luis M Montuenga, and Javier J Zulueta.
• Departamento de Neumología, Clínica Universidad de Navarra, Pamplona, España.
• Arch. Bronconeumol. 2015 Apr 1;51(4):169-76.

Introduction And ObjectivesEuropean experience regarding lung cancer screening using low-dose chest CT (LDCT) is available. However, there is limited data on the Spanish experience in this matter. Our aim is to present the results from the longest ongoing screening program in Spain.MethodologyThe Pamplona International Early Lung Cancer Detection Program (P-IELCAP) is actively screening participants for lung cancer using LDCT since year 2000 following the IELCAP protocol, including spirometric assessments. Men and women, ≥40 years of age, current or former smokers with a tobacco history of ≥10 pack-years are included. Results are compared to those from other European trials.ResultsA total of 2989 participants were screened until March 2014 (73% male). A median of 2 (IQR 1-3) annual screening rounds were performed. Sixty lung cancers were detected in 53 participants (73% in StageI). Adenocarcinoma was the most frequent. The lung cancer prevalence and incidence proportion was 1.0% and 1.4%, respectively, with an annual detection rate of 0.41. The estimated 10-year survival rate among individuals with lung cancer was 70%. Chronic obstructive pulmonary disease and emphysema are important lung cancer predictors.ConclusionsThe experience in Spain's longest lung cancer screening program is comparable to what has been described in the rest of Europe, and confirms the feasibility and efficacy of lung cancer screening using LDCT.Copyright © 2014 SEPAR. Published by Elsevier Espana. All rights reserved.

45 keywords...

hide…